Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact
Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: ENAH

Gene summary for ENAH

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

ENAH

Gene ID

55740

Gene nameENAH actin regulator
Gene AliasENA
Cytomap1q42.12
Gene Typeprotein-coding
GO ID

GO:0000902

UniProtAcc

Q8N8S7


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
55740ENAHP37T-EHumanEsophagusESCC1.65e-369.40e-010.1371
55740ENAHP38T-EHumanEsophagusESCC3.43e-053.77e-010.127
55740ENAHP39T-EHumanEsophagusESCC4.50e-102.16e-010.0894
55740ENAHP40T-EHumanEsophagusESCC3.04e-197.63e-010.109
55740ENAHP42T-EHumanEsophagusESCC1.72e-248.37e-010.1175
55740ENAHP44T-EHumanEsophagusESCC6.92e-115.21e-010.1096
55740ENAHP47T-EHumanEsophagusESCC1.21e-134.65e-010.1067
55740ENAHP48T-EHumanEsophagusESCC1.53e-164.17e-010.0959
55740ENAHP49T-EHumanEsophagusESCC2.11e-182.82e+000.1768
55740ENAHP52T-EHumanEsophagusESCC4.81e-317.31e-010.1555
55740ENAHP54T-EHumanEsophagusESCC3.03e-235.92e-010.0975
55740ENAHP56T-EHumanEsophagusESCC5.55e-061.22e+000.1613
55740ENAHP57T-EHumanEsophagusESCC3.61e-113.53e-010.0926
55740ENAHP61T-EHumanEsophagusESCC2.70e-144.17e-010.099
55740ENAHP62T-EHumanEsophagusESCC8.37e-356.12e-010.1302
55740ENAHP65T-EHumanEsophagusESCC7.72e-316.51e-010.0978
55740ENAHP74T-EHumanEsophagusESCC5.04e-297.97e-010.1479
55740ENAHP75T-EHumanEsophagusESCC1.64e-245.03e-010.1125
55740ENAHP76T-EHumanEsophagusESCC4.60e-399.44e-010.1207
55740ENAHP79T-EHumanEsophagusESCC1.26e-235.79e-010.1154
Page: 1 2 3 4 5 6 7 8 9 10 11 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
BreastThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.IDC: Invasive ductal carcinoma
DCIS: Ductal carcinoma in situ
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
CervixThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.CC: Cervix cancer
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
N_HPV: HPV-infected normal cervix
EndometriumThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AEH: Atypical endometrial hyperplasia
EEC: Endometrioid Cancer
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
LungThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AAH: Atypical adenomatous hyperplasia
AIS: Adenocarcinoma in situ
IAC: Invasive lung adenocarcinoma
MIA: Minimally invasive adenocarcinoma
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
ProstateThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.BPH: Benign Prostatic Hyperplasia
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:00070159BreastPrecanceractin filament organization44/1080442/187233.02e-044.35e-0344
GO:000701514BreastIDCactin filament organization55/1434442/187232.45e-043.84e-0355
GO:000701524BreastDCISactin filament organization56/1390442/187235.90e-051.19e-0356
GO:000701510CervixCCactin filament organization109/2311442/187234.92e-132.45e-10109
GO:00081549CervixCCactin polymerization or depolymerization51/2311218/187234.05e-061.05e-0451
GO:00615647CervixCCaxon development89/2311467/187231.71e-053.27e-0489
GO:00074097CervixCCaxonogenesis78/2311418/187231.14e-041.43e-0378
GO:000701516EndometriumAEHactin filament organization98/2100442/187231.99e-112.98e-0998
GO:00074098EndometriumAEHaxonogenesis81/2100418/187235.54e-072.12e-0581
GO:00615648EndometriumAEHaxon development88/2100467/187236.39e-072.38e-0588
GO:000815410EndometriumAEHactin polymerization or depolymerization44/2100218/187237.64e-051.15e-0344
GO:000701517EndometriumEECactin filament organization95/2168442/187231.31e-091.09e-0795
GO:006156412EndometriumEECaxon development93/2168467/187239.60e-084.69e-0693
GO:000740912EndometriumEECaxonogenesis82/2168418/187231.03e-063.49e-0582
GO:000815415EndometriumEECactin polymerization or depolymerization44/2168218/187231.59e-042.00e-0344
GO:000701527EsophagusESCCactin filament organization259/8552442/187232.37e-084.50e-07259
GO:000815420EsophagusESCCactin polymerization or depolymerization130/8552218/187232.19e-051.88e-04130
GO:006156415EsophagusESCCaxon development251/8552467/187232.41e-041.49e-03251
GO:000740915EsophagusESCCaxonogenesis219/8552418/187233.14e-031.31e-02219
GO:000701512LiverCirrhoticactin filament organization171/4634442/187233.93e-112.30e-09171
Page: 1 2 3 4 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
hsa0481014BreastIDCRegulation of actin cytoskeleton36/867229/84655.79e-033.13e-022.34e-0236
hsa0481015BreastIDCRegulation of actin cytoskeleton36/867229/84655.79e-033.13e-022.34e-0236
hsa0481023BreastDCISRegulation of actin cytoskeleton35/846229/84656.89e-033.37e-022.48e-0235
hsa0481033BreastDCISRegulation of actin cytoskeleton35/846229/84656.89e-033.37e-022.48e-0235
hsa0481016CervixCCRegulation of actin cytoskeleton64/1267229/84652.24e-072.59e-061.53e-0664
hsa0401512CervixCCRap1 signaling pathway56/1267210/84656.23e-065.61e-053.32e-0556
hsa043609CervixCCAxon guidance47/1267182/84658.13e-055.38e-043.18e-0447
hsa0481017CervixCCRegulation of actin cytoskeleton64/1267229/84652.24e-072.59e-061.53e-0664
hsa0401513CervixCCRap1 signaling pathway56/1267210/84656.23e-065.61e-053.32e-0556
hsa0436012CervixCCAxon guidance47/1267182/84658.13e-055.38e-043.18e-0447
hsa0401514EndometriumAEHRap1 signaling pathway49/1197210/84652.03e-041.78e-031.30e-0349
hsa0481018EndometriumAEHRegulation of actin cytoskeleton50/1197229/84659.08e-045.78e-034.23e-0350
hsa0436010EndometriumAEHAxon guidance39/1197182/84654.47e-032.46e-021.80e-0239
hsa0401515EndometriumAEHRap1 signaling pathway49/1197210/84652.03e-041.78e-031.30e-0349
hsa0481019EndometriumAEHRegulation of actin cytoskeleton50/1197229/84659.08e-045.78e-034.23e-0350
hsa0436013EndometriumAEHAxon guidance39/1197182/84654.47e-032.46e-021.80e-0239
hsa0401522EndometriumEECRap1 signaling pathway49/1237210/84654.45e-043.47e-032.59e-0349
hsa0481024EndometriumEECRegulation of actin cytoskeleton49/1237229/84653.20e-031.78e-021.33e-0249
hsa0436022EndometriumEECAxon guidance39/1237182/84657.78e-033.66e-022.73e-0239
hsa0401532EndometriumEECRap1 signaling pathway49/1237210/84654.45e-043.47e-032.59e-0349
Page: 1 2 3 4 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
ENAHSNVMissense_Mutationnovelc.599N>Cp.Arg200Prop.R200PQ8N8S7protein_codingtolerated_low_confidence(0.25)benign(0.226)TCGA-A2-A3XX-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapycyclophosphamideCR
ENAHSNVMissense_Mutationnovelc.678N>Tp.Arg226Serp.R226SQ8N8S7protein_codingdeleterious_low_confidence(0.04)benign(0)TCGA-A8-A06P-01Breastbreast invasive carcinomaFemale<65III/IVUnspecificSD
ENAHSNVMissense_Mutationc.1268C>Ap.Ser423Tyrp.S423YQ8N8S7protein_codingdeleterious(0.01)possibly_damaging(0.898)TCGA-AC-A23H-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownPD
ENAHSNVMissense_Mutationc.292A>Gp.Asn98Aspp.N98DQ8N8S7protein_codingdeleterious(0)probably_damaging(0.917)TCGA-AR-A1AH-01Breastbreast invasive carcinomaFemale<65I/IIUnspecificPD
ENAHSNVMissense_Mutationc.1169N>Tp.Thr390Ilep.T390IQ8N8S7protein_codingdeleterious(0)probably_damaging(0.968)TCGA-E9-A1R5-01Breastbreast invasive carcinomaFemale<65I/IIHormone TherapytamoxiphenSD
ENAHSNVMissense_Mutationc.1312N>Tp.Pro438Serp.P438SQ8N8S7protein_codingtolerated(0.27)probably_damaging(0.982)TCGA-S3-AA10-01Breastbreast invasive carcinomaFemale>=65I/IIChemotherapycytoxanCR
ENAHdeletionFrame_Shift_Delnovelc.673delGp.Glu225ArgfsTer27p.E225Rfs*27Q8N8S7protein_codingTCGA-D8-A27V-01Breastbreast invasive carcinomaFemale<65I/IIHormone TherapytamoxiphenSD
ENAHSNVMissense_Mutationrs549324711c.1450G>Ap.Ala484Thrp.A484TQ8N8S7protein_codingtolerated(0.07)benign(0.074)TCGA-C5-A1M7-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
ENAHSNVMissense_Mutationc.1432N>Ap.Glu478Lysp.E478KQ8N8S7protein_codingdeleterious(0.01)probably_damaging(0.941)TCGA-EK-A3GJ-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
ENAHSNVMissense_Mutationnovelc.256N>Cp.Val86Leup.V86LQ8N8S7protein_codingdeleterious(0)possibly_damaging(0.844)TCGA-HM-A4S6-01Cervixcervical & endocervical cancerFemale<65III/IVChemotherapycisplatinCR
Page: 1 2 3 4 5 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1